Lucid Diagnostics Inc. · NASDAQ:LUCD

Lucid Diagnostics — Q1 2025 Earnings Presentation

14 slides from Lucid Diagnostics's earnings presentation, May 14, 2025

  1. Slide 1: Q1 2025 Business Update

    Nasdaq: LUCD Q1 2025 Business Update May 14, 2025 Lishan Aklog MD Dennis McGrath Chairman & CEO CFO

  2. Slide 2: Disclaimer

    Disclaimer ▪ This presentation may contain certain forward-looking statements related to or Lucid Diagnostics Inc. (the “Company”) that involve risks and uncertainties. ▪ Actual results and events may differ significantly from results and events discussed in forward- looking statements. ▪ Factors th

  3. Slide 3: Lishan Aklog, M.D. Chairman & CEO

    Lishan Aklog, M.D. Chairman & CEO

  4. Slide 4: Highlights

    Highlights ▪ Commercial Execution – 1Q25 EsoGuard test volume: 3,034 – 1Q25 Revenue: $0.8M – Launched “Embrace the Future” campaign – Partnered with a major health system to launch comprehensive EsoGuard esophageal precancer testing program – Continued momentum executing concierge medicine contracts

  5. Slide 5: Highlights

    Highlights ▪ Key Strategic Accomplishments – Strengthened balance sheet with underwritten public offering of common stock, netting approximately $16.1 million in proceeds – NCI-sponsored study showed EsoGuard effectively detects esophageal precancer in at-risk patients without GERD symptoms, support

  6. Slide 6: Business Update

    Dlucid wes By Business Update

  7. Slide 7: Reimbursement Update

    D) Lucid” Reimbursement Update SHIGHMARK. National Comprehensive (een Cancer Network® PALMETTO © CCMS CENTERS FOR MEDICARE & MEDICAID SERVICES MolIDX

  8. Slide 8: "Embrace the Future" Campaign

    “Embrace the Future” Campaign 8

  9. Slide 9: Q1 2025 Financial Update

    Q1 2025 Financial Update Dennis McGrath, CFO

  10. Slide 10: Balance Sheet

    Balance Sheet ($ in thousands) 1Q25 4Q24 Change Assets Cash $25,238 $22,358 $2,880 Fixed Assets 1,040 1,062 (22) All other Assets 6,517 7,295 (778) Liabilities Accounts Payable 829 1,241 (412) Senior Secured Convertible Notes 32,800 18,600 14,200 Other Current Liabilities 2,940 3,683 (743) Long-Term

  11. Slide 11: P&L

    P&L ($ in thousands) 1Q25 1Q24 Change Revenue $828 $1,001 $(173) Operating Expenses $13,315 $11,793 $1,522 Net Loss $(26,908) $(10,612) $(16,296) 1 EBITDA $(26,744) $(10,167) $(16,577) Stock-Based Compensation $1,030 $933 $97 2 Non-GAAP Adjusted Loss $(11,162) $(9,335) $(1,827) Non-GAAP Adjusted Los

  12. Slide 12: Non-GAAP Operating Expense

    Non-GAAP Operating Expense To supplement our unaudited financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company’s financial results. Non-GAAP financial measures are presented with the i

  13. Slide 13: Q&A

    Q&A

  14. Slide 14: Closing Remarks

    Dlucid wes By Closing Remarks

Lucid Diagnostics — Q1 2025 Earnings Presentation on 6ix